Phacilitate Leaders World

Advanced Therapies Summit in association with FierceBiotech

Advanced Therapies Summit in association with FierceBiotech

January 22nd, 2019



Taking a strategic, patient-focused view of integrating advanced therapies into healthcare. Panel style discussions will be hosted by FierceBiotech’s Editorial team, designed for a C-suite audience.

  *Limited seats available, to book yours - please call Jeremy Roden on +44 (0)20 7384 7745.*







12pm – Register & Networking Lunch

1:25pm – Welcome address

1:30pm – Attracting investment while expanding your manufacturing base

  • With cell and gene therapies typically requiring higher amounts of capital compared to other biotech ventures – and 2018 being a banner year for biotech VC funding & IPOs – how can companies mitigate risks and attract investments while looking to scale up production?
  • What are investors looking for in companies deciding to make that transition?
  • What are the future concerns in manufacturing as the field turns toward larger patient populations and earlier lines of therapy?
  • Are there examples to learn from, with Allogene holding a record-breaking IPO while it’s lead program is in Phase 1?
    Panellists will be announced shortly


  • Conor Hale, Associate Editor, FierceBiotech
  • Derek Hei, Senior VP of Manufacturing, BlueRock Therapeutics 
  • Chris Stevens, Head of Manufacturing, Spark Therapeutics 
  • David Smith, Chief Commercial Officer, Healios
  • Kim Warren, Head of Operations, AVROBIO

2:30pm Refreshment break

2:45pm – How the embrace of alternative payment models will affect the development of future gene and cell therapies
When Novartis won FDA approval for its CAR-T, Kymriah, to treat some blood cancers last year, it struck a deal with the Centers for Medicare and Medicaid Services that allows for full payment only for patients who respond within one month. Spark also formed alternative payment deals around its gene therapy for retinitis pigmentosa, Luxturna.
What other ideas aside from pay-for-performance are being pursued? How involved is the payer community likely to be in shaping these deals going forward? And how should R&D professionals in biopharma incorporate the demand for alternative payment arrangements into the development process?

  • Arlene Weintraub, Journalist, FierceBiotech
  • Knut Niss, Chief Technology Officer, MustangBio
  • Usman “Oz” Asam, President & CEO, TMunity
  • Bill Martin, VP and Chief Commercial Officer, Accredo, a division of Express Scripts
  • Dave Lennon, President, AveXis, Inc

3:45pm – Additional Q&A

4:00pm – Networking Drinks

Ticket price


Please note: you have to register for the Phacilitate Leaders World to be eligible to attend the Advanced Therapies Summit in association with FierceBiotech


* subject to availability 

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman